Contact
searchSearch
HMP Global
Login
Quiz

Neoadjuvant FOLFIRINOX for Resectable or Borderline Resectable Pancreatic Ductal Adenocarcinoma

11/25/2025

Related Content

James Cleary, MD, PhD, Dana-Farber Cancer Institute
Videos
Treatment Sequencing in BRCA-Mutated Pancreatic Cancer
01/19/2026
James Cleary, MD, PhD
James Cleary, MD, PhD, discusses a case demonstrating how molecularly guided therapy in a patient with BRCA2-mutated metastatic pancreatic cancer led to exceptional and durable disease control with platinum-based chemotherapy followed by...
James Cleary, MD, PhD, discusses a case demonstrating how molecularly guided therapy in a patient with BRCA2-mutated metastatic pancreatic cancer led to exceptional and durable disease control with platinum-based chemotherapy followed by...
James Cleary, MD, PhD, discusses...
01/19/2026
Oncology
News
Microwave Ablation Plus Dual Checkpoint Inhibition Enhances Immune Response in Locally Advanced Pancreatic Ductal Adenocarcinoma
11/19/2025
Stephanie Holland
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and tremelimumab with microwave tumor ablation and chemotherapy demonstrated encouraging progression-free survival and potential immune modulation among patients with unresectable, non-metastatic, locally advanced...
Combining dual durvalumab and...
11/19/2025
Oncology
Michele Reni, MD
Conference Coverage
Neoadjuvant PAXG Significantly Improves Survival Compared to mFOLFIRNOX in Patients With Pancreatic Ductal Adenocarcinoma
07/24/2025
Michele Reni
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses results from the phase 3 CASSANDRA trial which demonstrated that neoadjuvant PAXG significantly improved event-free survival compared to mFOLFIRNOX among patients with resectable or borderline resectable pancreatic...
Michele Reni, MD, discusses...
07/24/2025
Oncology
News
Potential Activity of Afatinib Among Patients With Advanced Solid Tumors With NGR1 Fusions
05/06/2025
Allison Casey
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.
According to a case series of patients enrolled in the TAPUR trial, afatinib showed promising activity among patients with advanced solid tumors harboring neuregulin 1 fusions.
According to a case series of...
05/06/2025
Oncology

Recent News

News
Incidence of Cutaneous Squamous Cell Carcinoma and Carcinoma in Situ Continues to Rise
01/29/2026
Stephanie Holland
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world analysis have demonstrated that the incidence of cutaneous squamous cell carcinoma and cutaneous squamous cell carcinoma in situ has steadily increased over the past 2 decades, emphasizing the need for monitoring...
Results from a real-world...
01/29/2026
Oncology
News
Elenagen Plus Gemcitabine Improves Overall Survival for Patients With Platinum-Resistant Ovarian Cancer
01/29/2026
Emily Estrada
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to gemcitabine therapy significantly prolonged overall survival among patients with platinum-resistant ovarian cancer without increasing toxicity, according to results from a phase 2 trial.
The addition of elenagen to...
01/29/2026
Oncology
News
Axicabtagene Ciloleucel Plus Atezolizumab Demonstrates Promise in Relapsed/Refractory Large B-Cell Lymphoma
01/28/2026
Stephanie Holland
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2 ZUMA-6 trial showed that the addition of atezolizumab to axicabtagene ciloleucel showed promising clinical activity among patients with relapsed or refractory large B-cell lymphoma.
Results from the phase 1/2...
01/28/2026
Oncology
News
Advances in Antibody-Based Therapies for the Treatment of Relapsed Small-Cell Lung Cancer
01/27/2026
Gina Tomaine
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are reshaping the treatment paradigm for relapsed SCLC by enabling antigen-specific targeting with clinically meaningful activity beyond traditional chemotherapy, according to findings from a comprehensive review.
Antibody-based therapies are...
01/27/2026
Oncology
News
Tucatinib Plus Trastuzumab Shows Durable Efficacy and Manageable Safety for HER2-Posititive Metastatic Colorectal Cancer: MOUNTAINEER Trial
01/27/2026
Emily Estrada
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab provided durable responses and a favorable safety profile among patients with chemotherapy-refractory, HER2positive metastatic colorectal cancer, based on results from the phase 2 MOUNTAINEER trial.
Tucatinib plus trastuzumab...
01/27/2026
Oncology
News
TOMOX-Bevacizumab Combination Shows Feasibility as Second-Line Therapy in mCRC
01/27/2026
Emily Estrada
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination demonstrated an acceptable safety profile as a second-line treatment for patients with metastatic colorectal cancer progressing after irinotecan-based chemotherapy, according to a phase 2 study.
A TOMOX-bevacizumab combination...
01/27/2026
Oncology
News
ISL1 Emerges as a Potential Predictive Biomarker for Efficacy of Lurbinectedin in Relapsed SCLC
01/27/2026
Gina Tomaine
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified ISL1 as a potential predictive biomarker in small cell lung cancer, defining a subtype with enhanced sensitivity to lurbinectedin and supporting biomarker-driven patient selection in future trials.
A translational study identified...
01/27/2026
Oncology
News
CSF-1-Targeted Therapies Continue to Redefine Systemic Treatment for TGCT
01/26/2026
Gina Tomaine
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition provides an effective option for unresectable or recurrent tenosynovial giant cell tumor, with safety and tolerability favoring newer agents and potentially shifting first-line treatment paradigms.
Systemic CSF-1R inhibition...
01/26/2026
Oncology
News
Sacituzumab Govitecan Plus Pembrolizumab Significantly Prolongs PFS in PD-L1-Positive Triple-Negative Breast Cancer
01/22/2026
Stephanie Holland
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3 ASCENT-04 trial demonstrate that sacituzumab govitecan plus pembrolizumab significantly prolongs PFS compared to pembrolizumab plus chemotherapy among previously untreated patients with advanced, PD-L1–positive...
Results from the phase 3...
01/22/2026
Oncology
News
Anbenitamab Plus Chemotherapy After Trastuzumab Failure in HER2-Positive G/GEJ Cancer
01/21/2026
Stephanie Holland
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter, phase 3 trial demonstrated that anbenitamab plus chemotherapy improved survival compared with placebo plus chemotherapy among previously treated patients with HER2-positive gastric or gastroesophageal junction...
Results from a multicenter,...
01/21/2026
Oncology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use